News

The increase in revenue was due to $44.2m of profit share earned from commercial sales of Enoxaparin sodium injection and the $5m regulatory milestone earned upon FDA marketing

Acorda has posted a net income of $12.44m for the third quarter 2010, or $0.31 per diluted share, compared to net loss of $19.43m, or $0.51 loss per

Coombs is appointed to the Audit and Corporate Governance Committees while Fischer is appointed to the Audit and Compensation Committees. Coombs, retired since 2008 from Tetra Technologies, served

In the CRL, the FDA has asked additional information in relation to the Linjeta (human insulin [rDNA origin]) injection 100IU/ml NDA for the treatment of type 1 and

Migalastat HCl is an investigational treatment for fabry disease and has the potential to be the first in a new class of oral, small molecule medicines called pharmacological

This accelerated approval of Afinitor is based on an open-label, single-arm, 28-patient study conducted by Cincinnati Children’s Hospital Medical Center. The effectiveness of Afinitor is based on an

According to Roche, the EC approval is based on the results from the phase III Prima study which demonstrated that continuing MabThera for two years (maintenance treatment) in

Caraco Pharma has posted a net loss of $1.51m for the second quarter 2010, or $0.04 loss per diluted share, compared to net income of $6.67m, or $0.16

Dyadem claimed that it has expanded in response to a surge in customer demand in the EU for its enterprise risk management software and services amid heightened scrutiny